Announcements

July is Sarcoma and Bone Cancer Awareness Month, and various global activities are aiming to highlight and increase the awareness of sarcoma and bone cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of sarcoma and bone cancer, which were published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“Classification of Chondrosarcoma: From Characteristic to Challenging Imaging Findings”
by Jun-Ho Kim and Seul Ki Lee
Cancers 2023, 15(6), 1703; https://doi.org/10.3390/cancers15061703
Available online: https://www.mdpi.com/2072-6694/15/6/1703

“Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin”
by Valentina Fausti, Alessandro De Vita, Silvia Vanni, Virginia Ghini, Lorena Gurrieri, Nada Riva, Roberto Casadei, Marco Maraldi, Giorgio Ercolani, Davide Cavaliere et al.
Cancers 2023, 15(4), 1080; https://doi.org/10.3390/cancers15041080   
Available online: https://www.mdpi.com/2072-6694/15/4/1080

“Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis”
by Bikesh K. Nirala, Taku Yamamichi, D. Isabel Petrescu, Tasnuva N. Shafin and Jason T. Yustein
Cancers 2023, 15(20), 5108; https://doi.org/10.3390/cancers15205108  
Available online: https://www.mdpi.com/2072-6694/15/20/5108

“Osteosarcoma in Pediatric and Adult Populations: Are Adults Just Big Kids?”
by Caleb Kim, Lara E. Davis, Catherine M. Albert, Brian Samuels, Jesse L. Roberts and Michael J. Wagner
Cancers 2023, 15(20), 5044; https://doi.org/10.3390/cancers15205044
Available online: https://www.mdpi.com/2072-6694/15/20/5044

“SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma”
by Erlinda Maria Gordon, Sant P. Chawla, Walter Andree Tellez, Elan Younesi, Sonu Thomas, Victoria S. Chua-Alcala, Hripsime Chomoyan, Chrysler Valencia, Don Arlen Brigham, Ania Moradkhani et al.
Cancers 2023, 15(3), 906; https://doi.org/10.3390/cancers15030906  
Available online: https://www.mdpi.com/2072-6694/15/3/906

“Application of Machine Learning for Differentiating Bone Malignancy on Imaging: A Systematic Review”
by Wilson Ong, Lei Zhu, Yi Liang Tan, Ee Chin Teo, Jiong Hao Tan, Naresh Kumar, Balamurugan A. Vellayappan, Beng Chin Ooi, Swee Tian Quek, Andrew Makmur et al.
Cancers 2023, 15(6), 1837; https://doi.org/10.3390/cancers15061837  
Available online: https://www.mdpi.com/2072-6694/15/6/1837

“Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group”
by Bettina Jansko-Gadermeir, Michael Leisch, Franz J. Gassner, Nadja Zaborsky, Thomas Dillinger, Sonja Hutter, Angela Risch, Thomas Melchardt, Alexander Egle, Manuel Drost et al.
Cancers 2023, 15(8), 2305; https://doi.org/10.3390/cancers15082305
Available online: https://www.mdpi.com/2072-6694/15/8/2305

“Endogenous Extracellular Matrix Regulates the Response of Osteosarcoma 3D Spheroids to Doxorubicin”
by Margherita Cortini, Francesca Macchi, Francesca Reggiani, Emanuele Vitale, Maria Veronica Lipreri, Francesca Perut, Alessia Ciarrocchi, Nicola Baldini and Sofia Avnet
Cancers 2023, 15(4), 1221; https://doi.org/10.3390/cancers15041221  
Available online: https://www.mdpi.com/2072-6694/15/4/1221

“Deep Learning Approaches to Osteosarcoma Diagnosis and Classification: A Comparative Methodological Approach”
by Ioannis A. Vezakis, George I. Lambrou and George K. Matsopoulos
Cancers 2023, 15(8), 2290; https://doi.org/10.3390/cancers15082290
Available online: https://www.mdpi.com/2072-6694/15/8/2290

“Pragmatic, Prospective Comparative Effectiveness Trial of Carbon Ion Therapy, Surgery, and Proton Therapy for the Management of Pelvic Sarcomas (Soft Tissue/Bone) Involving the Bone: The PROSPER Study Rationale and Design”
by Bradford S. Hoppe, Ivy A. Petersen, Benjamin K. Wilke, Todd A. DeWees, Reiko Imai, Eugen B. Hug, Maria Rosaria Fiore, Jürgen Debus, Piero Fossati, Shigeru Yamada et al.
Cancers 2023, 15(6), 1660; https://doi.org/10.3390/cancers15061660
Available online: https://www.mdpi.com/2072-6694/15/6/1660

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office

According to the World Health Organization, cancer is a leading cause of mortality and accounted for approximately 10 million deaths in 2020. Therefore, continued research regarding understanding, diagnosing, and treating cancer is a global priority. The ever-evolving field of oncology spans innovations and discoveries in tumor biology, immunotherapy, targeted treatments, early detection, and personalized medicine.

The mission of MDPI’s cluster of oncology-related journals is to publish high-impact research with potential to redefine cancer treatment and care. Addressing topics from solid tumors to hematologic malignancies, from rare cancers to novel therapeutics, these journals provide a dynamic platform for groundbreaking discoveries and clinical advancements that shape the future of oncology.

The four participating journals are as follows:

• Cancers (ISSN: 2072-6694) focuses on publishing high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics. In particular, it showcases the most seminal studies in the rapidly growing areas of immunology, immunotherapy, and tumor microenvironment research. Cancers is led by its Editor-in-Chief, Prof. Dr. Samuel C. Mok;
• Current Oncology (ISSN: 1718-7729) is dedicated to advancing cancer care and therapy via publishing clinically relevant research with direct applications to oncology practice. Since its establishment in 1994, the journal has played an important role in disseminating new knowledge across the entire cancer care continuum, spanning the prevention, early detection, and diagnosis of cancer; treatment, including systemic therapy, radiation therapy, and surgery; supportive care; and survivorship care. Additionally, it highlights the critical role of biomarkers and biomarker-driven research in guiding personalized oncology. Affiliated with several key cancer societies, Current Oncology provides a global platform to share scientific progress in oncology. The journal is led by its Editor-in-Chief, Prof. Dr. Shahid Ahmed;
• Onco (ISSN: 2673-7523) functions as a scientific forum integrating novel preclinical, translational, and clinical cancer research and is focused on (but not limited to) the following topics: cancer cell signaling; cancer genetics and molecular targets; cancer epigenetics and heterogeneity; carcinogenesis and cancer evolution; microbiomes and cancer; cancer metabolomics; cancer biomarkers; cancer dormancy; novel targeted and immune cancer therapies; randomized clinical trials; oncotargets; cancer therapies; and clinical reports proposing novel therapeutic regimens. Onco is led by its Editor-in-Chief, Dr. Constantin N. Baxevanis;
• Targets (ISSN: 2813-3137) is centered on, but not limited to, discovering novel molecules which act as diagnostic biomarkers and therapeutic targets, establishing new bionic recognition systems for biosensing and bioimaging, developing novel approaches for biomarker detection, related applications of biological interaction monitoring and targeted therapy, designing new signal amplification strategies for biosensing and cellular or in vivo imaging, utilizing molecular recognition for single-molecule or single-cell analysis, elucidating new pathways or mechanisms in disease development and progression, and synthesizing smart nanomaterials for activatable imaging and responsive drug release. Targets is led by its Editor-in-Chief, Prof. Dr. Huangxian Ju.

MDPI’s mission and values:

As a pioneer in academic open access publishing, MDPI has been serving the scientific community since 1996. Our aim is to foster scientific exchange in all forms and across all disciplines. MDPI's guidelines for disseminating open science are based on the following values and guiding principles:

• Open Access—All our content is published in open access format and distributed under a Creative Commons License, providing free access to the latest research and allowing articles to be freely shared and content to be re-used with proper attribution;
• Timeliness and Efficiency—We rapidly publish novel research through a thorough editorial process, ensuring that a first decision is provided to authors in under 32 days and that papers are published within 7–10 days upon acceptance;
• Simplicity—We offer user-friendly tools and services on our integrated system to enhance the efficiency of our editorial process;
• High-Quality Service—We support scholars and their work by providing a range of options, such as publication in journals at mdpi.com, early publication at preprints.org, and the publication of conferences at sciforum.net, to positively impact research;
• Flexibility—We adapt and develop new tools and services to meet the changing needs of the research community, driven by feedback from authors, editors, and readers;
• Rooted in Sustainability—We ensure the long-term preservation of published papers and support the future of science through partnerships, sponsorships, and awards.

By adhering to these values and principles, MDPI remains committed to advancing scientific knowledge and promoting open-science practices.

Selected Topics:

• “Cancer Biology and Radiation Therapy: 2nd Edition”;
• “Hepatobiliary and Pancreatic Diseases: Novel Strategies of Diagnosis and Treatments”;
• “Biomarkers of Disease: Discovery and Clinical Applications”;
• “Recent Advances in Anticancer Strategies, 2nd Edition”.

Selected Articles:

Cancers
“Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer Treatment”
Cancers 2024, 16(12), 2171; https://doi.org/10.3390/cancers16122171

Current Oncology
“Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse”
Curr. Oncol. 2023, 30(2), 2322-2347; https://doi.org/10.3390/curroncol30020179

Onco
“Significance of PET/CT Imaging in Myeloma Assessment: Exploring Novel Applications beyond Osteolytic Lesion Detection and Treatment Response”
Onco 2024, 4(1), 15-36; https://doi.org/10.3390/onco4010002

Targets
“Potential of MMP-2 and MMP-9 Gelatinase Blockade as a Therapeutic Strategy in Fibrosarcoma Treatment: A Decadal Review”
Targets 2024, 2(2), 104-125; https://doi.org/10.3390/targets2020007

Six new journals covering a range of subjects launched their inaugural issues in June 2025. We are excited to be able to share with you the newest research rooted in the value of open access. We are pleased to present the latest research and to make it accessible to all.

We extend our sincere thanks to all the Editorial Board Members for their commitment and expertise. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

Journal	Founding Editor-in-Chief	Journal Topics (Selected)
	Prof. Dr. Chang-Pu Sun, China Academy of Engineering Physics, Beijing, China; Computational Science Research Center, China Editorial | View inaugural issue	quantum information and phenomena; condensed matter physics and statistical physics; atomic, molecular, and optical physics; computational physics and mathematical methods View journal scope | Submit an article
	Prof. Dr. Hualiang Lin, Sun Yat-sen University, China; Prof. Dr. Jose L. Domingo, Universitat Rovira i Virgili, Spain Editorial | View inaugural issue	green and organic food; green infrastructures; green exercise; environmental impact of the healthcare sector; effects of climate change on human health | View journal scope | Submit an article
	Prof. Dr. Francesco Veglio, University of L’Aquila, Italy Editorial | View inaugural issue	ultra-pure substances; water purification; air purification; gas purification; inorganic chemical purification; purification technologies View journal scope | Submit an article
	Prof. Dr. Junxing Zheng, Huazhong University of Science and Technology, China Editorial | View inaugural issue	computer-aided design and engineering; artificial intelligence and machine learning; building information modeling (BIM) and digital twins; robotics and automation in construction; smart sensors and Internet of Things (IoT); intelligent control systems and facilities management View journal scope | Submit an article
	Prof. Dr. Assunta Di Vaio, University of Naples Parthenope, Italy Editorial | View inaugural issue	sustainability, managerial, and biodiversity accounting; carbon management accounting; corporate social responsibility; artificial intelligence and disclosure View journal scope | Submit an article
	Prof. Dr. Changjun Liu, Sichuan University, China Editorial | View inaugural issue	bioeffects of electromagnetic waves; electromagnetic science and engineering; microwave, millimeter-wave, and terahertz technologies; metamaterials and metasurfaces; communication, sensing, and networks; energy, power, and sustainable applications; quantum and emerging technologies; artificial intelligence and advanced fabrication View journal scope | Submit an article

MDPI will be attending the 10th World Congress of the International Academy of Oral Oncology, which will be held from 16 to 19 July 2025 at the Arena and Conference (ACC) Liverpool in Liverpool, UK.

The International Academy of Oral Oncology (IAOO) is a multi-disciplinary community of clinicians and scientists working on issues relating to the etiopathogenesis, epidemiology, prevention and management or oral and perioral tumours of oral disease in patients with malignancies. The IAOO exists to bring together clinicians and scientists working in the field of oral oncology, so that advances in medical science can be achieved and quickly translated into benefits for patients.

The World Congress of the Academy is an opportunity for the IAOO community to meet and exchange ideas and innovations in the field of oral oncology. The Congress is the only global gathering of head and neck surgeons, radiation and medical oncologists, maxillo-facial surgeons, otorhinolaryngologists and all other allied specialists in oral cancer care.

The following open access journals will be represented at the conference:

• Cancers;
• CMTR;
• Current Oncology;
• Gastrointestinal Disorders;
• Oral;
• Surgeries.

If you are planning to attend, please do not hesitate to visit our booth. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit the following website: https://eu.eventscloud.com/website/14087/home/.

International Albinism Awareness Day 2025 underscores the urgent need for increased awareness, preventive care, and accessible healthcare for people with albinism. This year’s theme highlights the life-threatening impact of skin cancer among individuals with albinism and reinforces the importance of sun protection, early detection, and timely treatment.

Albinism is a rare, inherited genetic condition that affects the body’s ability to produce melanin, the pigment responsible for the color of our skin, hair, and eyes. People with albinism typically have very light skin and hair, alongside various vision impairments. While it is not contagious and does not affect intelligence, albinism is often misunderstood. This leads to stigmatization, discrimination, and even human rights violations in some regions where harmful myths persist.

Because they have little to no melanin, individuals with albinism are especially vulnerable to sun damage and face a significantly increased risk of developing skin cancer. Addressing this requires more than just clinical intervention—it calls for integrated healthcare policies and inclusive social systems that acknowledge both the medical and socio-political dimensions of the condition.

In recognition of this global observance, we invite you to explore a curated collection of articles and Special Issues from selected MDPI journals, including Biomedicines, Cancers, Children, Diagnostics, Genes, International Journal of Molecular Sciences, Journal of Clinical Medicine and Molecules. These open-access resources provide critical insights into the diagnosis, management, and complications of albinism, and promote cross-disciplinary collaboration between researchers, clinicians, and advocacy groups.

Together, through science, education, and empathy, we can foster a more inclusive world where people with albinism live free from discrimination and with access to the care they deserve.

“Can a Portable Flash Visual Evoked Potential (VEP) Device Identify Chiasmal Decussation Anomalies in Albinism?”
by Eloise Keeling, Perry Carter, Abdi Malik Musa, Fatima Shawkat, Helena Lee and Jay E. Self
Diagnostics 2025, 15(11), 1395; https://doi.org/10.3390/diagnostics15111395

“Common Variants in the TYR Gene with Unclear Pathogenicity as the Cause of Oculocutaneous Albinism in a Cohort of Russian Patients”
by Olga Shchagina, Anna Stepanova, Polina Mishakova, Vitaliy Kadyshev, Nina Demina, Ludmila Bessonova, Sofya Ionova, Daria Guseva, Andrey Marakhonov, Rena Zinchenko et al.
Biomedicines 2024, 12(10), 2234; https://doi.org/10.3390/biomedicines12102234

“Functional Characterization of Splice Variants in the Diagnosis of Albinism”
by Modibo Diallo, Cécile Courdier, Elina Mercier, Angèle Sequeira, Alicia Defay-Stinat, Claudio Plaisant, Shahram Mesdaghi, Daniel Rigden, Sophie Javerzat, Eulalie Lasseaux et al.
Int. J. Mol. Sci. 2024, 25(16), 8657; https://doi.org/10.3390/ijms25168657

“Genetic Linkage between CAPN5 and TYR Variants in the Context of Albinism and Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Absence: A Case Report”
by Mirjana Bjeloš, Ana Ćurić, Mladen Bušić, Benedict Rak and Biljana Kuzmanović Elabjer
Int. J. Mol. Sci. 2024, 25(12), 6442; https://doi.org/10.3390/ijms25126442

“Missing Heritability in Albinism: Deep Characterization of a Hungarian Albinism Cohort Raises the Possibility of the Digenic Genetic Background of the Disease”
by Nikoletta Nagy, Margit Pal, Jozsef Kun, Bence Galik, Peter Urban, Marta Medvecz, Beata Fabos, Alexandra Neller, Aliasgari Abdolreza, Judit Danis, Viktoria Szabo, Zhuo Yang, Stefanie Fenske, Martin Biel, Attila Gyenesei, Eva Adam and Marta Szell
Int. J. Mol. Sci. 2024, 25(2), 1271; https://doi.org/10.3390/ijms25021271

“Does Foveal Hypoplasia Affect Emmetropization in Patients with Albinism?”
by Line Kessel, Christine Dahlgren Bohnsack Kjølholm and Joaquim Torner Jordana
Children 2023, 10(12), 1910; https://doi.org/10.3390/children10121910

“Vision-Related Quality of Life in Danish Patients with Albinism and the Impact of an Updated Optical Rehabilitation”
by Kristian Lisbjerg, Joaquim Torner Jordana, Vibeke N. Brandt, Christine Kjølholm and Line Kessel
J. Clin. Med. 2023, 12(17), 5451; https://doi.org/10.3390/jcm12175451

“Skin Pigmentation Types, Causes and Treatment—A Review”
by Amin Mahmood Thawabteh, Alaa Jibreen, Donia Karaman, Alà Thawabteh and Rafik Karaman
Molecules 2023, 28(12), 4839; https://doi.org/10.3390/molecules28124839

“Report of Hermansky–Pudlak Syndrome in Two Families with Novel Variants in HPS3 and HPS4 Genes”
by Sadeeda Qaiser Zaman, Muhammad Anas, Gauhar Rehman, Qadeem Khan, Aiman Iftikhar, Mashal Ahmad, Muhammad Owais, Ilyas Ahmad, Osama Yousef Muthaffar, Angham Abdulrhman Abdulkareem et al.
Genes 2023, 14(1), 145; https://doi.org/10.3390/genes14010145

“Diagnostic Yield of Genetic Testing for Ocular and Oculocutaneous Albinism in a Diverse United States Pediatric Population”
by Kyle S. Chan, Brenda L. Bohnsack, Alexander Ing, Andy Drackley, Valerie Castelluccio, Kevin X. Zhang, Hanta Ralay-Ranaivo and Jennifer L. Rossen
Genes 2023, 14(1), 135; https://doi.org/10.3390/genes14010135

“More than Skin Deep—Latest Advances in Congenital and Autoimmune Pigmentation Disorders” Guest Editor: Prof. Dr. Reinhart M. Speeckaert Submission deadline: 25 August 2025	“Melanin Pigmentation: Physiology and Pathology” Guest Editors: Prof. Dr. Shosuke Ito and Prof. Dr. Manickam Sugumaran Submission deadline: 20 October 2025

June is Cancer Survivor Month, which is a month-long observance that celebrates the strength, resilience, and triumph of those who have battled cancer. We would like to take this opportunity to express our gratitude to all of the researchers who have contributed to this field. In particular, we would like to share some of the innovative research findings in fields concerning cancer survivors, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information regarding this field.

The list of the relevant papers can be found below:

“Improving Quality of Life and Psychosocial Health for Penile Cancer Survivors: A Narrative Review”
by Von Marie Torres Irizarry, Irasema Concepcion Paster, Vanessa Ogbuji, D’Andre Marquez Gomez, Kyle Mccormick and Juan Chipollini
Cancers 2024, 16(7),1309; https://doi.org/10.3390/cancers16071309
Available online: https://www.mdpi.com/2072-6694/16/7/1309

“Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model”
by Kimberley T. Lee, Hailey W. Bulls, Aasha I. Hoogland, Brian W. James, Claudia B. Colon-Echevarria and Heather S. L. Jim
Cancers 2024, 16(14), 2571; https://doi.org/10.3390/cancers16142571
Available online: https://www.mdpi.com/2072-6694/16/14/2571

“Reviewing the Landscape of Cancer Survivorship: Insights from Dr. Lidia Schapira’s Programs and Beyond”
by Viviana Cortiana, Rabab Hunaid Abbas, Soumiya Nadar, Diksha Mahendru, Jade Gambill, Gayathri Pramil Menon, Chandler H. Park and Yan Leyfman
Cancers 2024, 16(6), 1216; https://doi.org/10.3390/cancers16061216
Available online: https://www.mdpi.com/2072-6694/16/6/1216

“Impact of Real-World Outpatient Cancer Rehabilitation Services on Health-Related Quality of Life of Cancer Survivors across 12 Diagnosis Types in the United States”
by Mackenzi Pergolotti, Kelley C. Wood, Tiffany D. Kendig and Stacye Mayo
Cancers 2024, 16(10), 1927; https://doi.org/10.3390/cancers16101927  
Available online: https://www.mdpi.com/2072-6694/16/10/1927  

“Pain in Long-Term Cancer Survivors: Prevalence and Impact in a Cohort Composed Mostly of Breast Cancer Survivors”
by Concepción Pérez, Dolores Ochoa, Noelia Sánchez, Ana Isabel Ballesteros, Sheila Santidrián, Isabel López, Rebeca Mondéjar, Thiago Carnaval, Jesús Villoria and Ramón Colomer
Cancers 2024, 16(8), 1581; https://doi.org/10.3390/cancers16081581
Available online: https://www.mdpi.com/2072-6694/16/8/1581

“Household Income Is Associated with Chronic Pain and High-Impact Chronic Pain among Cancer Survivors: A Cross-Sectional Study Using NHIS Data”
by Nimish Valvi, Javier A. Tamargo, Dejana Braithwaite, Roger B. Fillingim and Shama D. Karanth
Cancers 2024, 16(16), 2847; https://doi.org/10.3390/cancers16162847
Available online: https://www.mdpi.com/2072-6694/16/16/2847

“The Cancer Patient Empowerment Program: A Comprehensive Approach to Reducing Psychological Distress in Cancer Survivors, with Insights from a Mixed-Model Analysis, Including Implications for Breast Cancer Patients”
by Gabriela Ilie, Gregory Knapp, Ashley Davidson, Stephanie Snow, Hannah M. Dahn, Cody MacDonald, Markos Tsirigotis and Robert David Harold Rutledge
Cancers 2024, 16(19), 3373; https://doi.org/10.3390/cancers16193373
Available online: https://www.mdpi.com/2072-6694/16/19/3373

“Role of Nutraceuticals in Counteracting Inflammation in In Vitro Macrophages Obtained from Childhood Cancer Survivors”
by Alessandra Di Paola, Maria Maddalena Marrapodi, Elvira Pota, Rosa Colucci Cante, Deeksha Rana, Giulia Giliberti, Giuseppe Di Feo, Shakeel Ahmed, Domenico Roberti, Roberto Nigro et al.
Cancers 2024, 16(4), 714; https://doi.org/10.3390/cancers16040714
Available online: https://www.mdpi.com/2072-6694/16/4/714

“Features of Studies on Transition Interventions for Childhood Cancer Survivors: A Scoping Review”
by Jun Ma, Xueling Xiao, Siqi Zhou, Can Gu, Fei Liu and Honghong Wang
Cancers 2024, 16(2), 272; https://doi.org/10.3390/cancers16020272
Available online: https://www.mdpi.com/2072-6694/16/2/272

“Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study”
by Nathalie Vanlaer, Iris Dirven, Bart Neyns and Anne Rogiers
Cancers 2024, 16(9), 1638; https://doi.org/10.3390/cancers16091638
Available online: https://www.mdpi.com/2072-6694/16/9/1638

“Impact of Pre-Diagnostic Risk Factors on Short- and Long-Term Ovarian Cancer Survival Trajectories: A Longitudinal Observational Study”
by Shana J. Kim, Shelley S. Tworoger, Barry P. Rosen, John R. McLaughlin, Harvey A. Risch, Steven A. Narod and Joanne Kotsopoulos
Cancers 2024, 16(5), 972; https://doi.org/10.3390/cancers16050972
Available online: https://www.mdpi.com/2072-6694/16/5/972

“The Role of Amide Proton Transfer (APT)-Weighted Imaging in Glioma: Assessment of Tumor Grading, Molecular Profile and Survival in Different Tumor Components”
by Gonçalo Borges de Almeida, Riccardo Pascuzzo, Francesca Mambrin, Domenico Aquino, Mattia Verri, Marco Moscatelli, Massimiliano Del Bene, Francesco DiMeco, Antonio Silvani, Bianca Pollo et al.
Cancers 2024, 16(17), 3014; https://doi.org/10.3390/cancers16173014  
Available online: https://www.mdpi.com/2072-6694/16/17/3014

“Characterization of Patient Activation among Childhood Cancer Survivors in the St. Jude Lifetime Cohort Study (SJLIFE)”
by Megan E. Ware, Angelica De La Cruz, Qian Dong, Kyla Shelton, Tara M. Brinkman, I-Chan Huang, Rachel Webster, Brian Potter, Kevin Krull, Sedigheh Mirzaei et al.
Cancers 2024, 16(18), 3220; https://doi.org/10.3390/cancers16183220
Available online: https://www.mdpi.com/2072-6694/16/18/3220

“Menopausal Hormone Therapy in Breast Cancer Survivors”
by Rose Culhane, Alexandra M. Zaborowski and Arnold D. K. Hill
Cancers 2024, 16(19), 3267; https://doi.org/10.3390/cancers16193267
Available online: https://www.mdpi.com/2072-6694/16/19/3267

You are welcome to submit relevant papers to Cancers.

We are pleased to share that Cancers (ISSN: 2072-6694) has received an increased CiteScore of 8.8 in June 2025. The CiteScore ranks the journal 68 out of 415 titles (Q1) in the “Oncology” category, an impressive achievement for a journal running in Volume 17.

You can find more statistics on our website.

The current CiteScores measure the average number of citations within a journal over a four-year window (2021–2024). The Scopus database provides a comprehensive suite of metrics that support informed publishing strategies, research evaluation and enable benchmarking of journal performance.

This achievement reflects the collective efforts of our authors, reviewers, and editors. Together we will continue to track the progress of Cancers and its growing impact in oncology.

We are pleased to announce that six new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694), joining in June 2025. We wish our new members success in both their research and their efforts to develop the journal.

Name: Prof. Dr. Aria Baniahmad
Affiliation: Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, Jena 07747, Germany
Interests: Androgen regulation of prostate cancer; Androgen receptor biology; Cellular senescence in cancer

Name: Prof. Dr. Daniele Generali
Affiliation: Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy
Interests: breast cancer; molecular oncology

Name: Dr. Jesus Garcia-Foncillas
Affiliation: Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Díaz-UAM, E-28040 Madrid, Spain
Interests: cancer biomarkers; oncology; precision medicine

Name: Prof. Dr. Marco Demaria
Affiliation: European Institute for the Biology of Aging (ERIBA), University Medical Center Groningen, University of Groningen, 9713 AV Groningen, the Netherlands
Interests: cellular senescence; molecular cancer biology; tumor microenvironment; responses to cancer treatment; aging; cell cycle arrest

Name: Prof. Dr. Michaela Luconi
Affiliation: Department of Experimental and Clinical Biomedical Sciences, Endocrinology Unit, University of Florence, I‐50139 Florence, Italy
Interests: adrenal tumors; molecular and cell biology of endocrine tumors and metabolic pathologies

Name: Dr. Stacey Edwards
Affiliation: Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia
Interests: molecular biology; gene regulation; noncoding RNAs; chromatin conformation; post-GWAS functional studies; breast cancer; ovarian cancer

Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.

Cancers is recruiting scholars from around the world to join our Editorial Board.

To apply for membership, recommend potential candidates, or request further information, please contact the Cancers Editorial Office and provide the following files:

• A full academic CV;
• A short cover letter detailing your interest in the position.

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the “Pediatric Oncology” Section, which are listed below.

1. “Therapeutic Parent–Child Communication and Health Outcomes in the Childhood Cancer Context: A Scoping Review”
by Heeyeon Son and Nani Kim
Cancers 2024, 16(11), 2152; https://doi.org/10.3390/cancers16112152
Available online: https://www.mdpi.com/2072-6694/16/11/2152

2. “Telomere Length in Adolescent and Young Adult Survivors of Childhood Cancer”
by Meerim Park, Dong-Eun Lee, Yuna Hong, Jin Kyung Suh, Jun Ah Lee, Myungshin Kim and Hyeon Jin Park
Cancers 2024, 16(13), 2344; https://doi.org/10.3390/cancers16132344
Available online: https://www.mdpi.com/2072-6694/16/13/2344

3. “Non-Syndromic and Syndromic Defects in Children with Extracranial Germ Cell Tumors: Data of 2610 Children Registered with the German MAKEI 96/MAHO 98 Registry Compared to the General Population”
by Judit H. Schultewolter, Anke Rissmann, Dietrich von Schweinitz, Michael Frühwald, Claudia Blattmann, Lars Fischer, Björn Sönke Lange, Rüdiger Wessalowski, Birgit Fröhlich, Wolfgang Behnisch et al.
Cancers 2024, 16(11), 2157; https://doi.org/10.3390/cancers16112157
Available online: https://www.mdpi.com/2072-6694/16/11/2157

4. “VISTA Emerges as a Promising Target against Immune Evasion Mechanisms in Medulloblastoma”
by Natalia Muñoz Perez, Juliana M. Pensabene, Phillip M. Galbo, Jr., Negar Sadeghipour, Joanne Xiu, Kirsten Moziak, Rita M. Yazejian, Rachel L. Welch, W. Robert Bell, Soma Sengupta et al.
Cancers 2024, 16(15), 2629; https://doi.org/10.3390/cancers16152629
Available online: https://www.mdpi.com/2072-6694/16/15/2629

5. “Acute Pancreatitis in Pediatric Acute Lymphoblastic Leukemia (AcuPA Study): A Nationwide Survey in Poland”
by Anna Morawiak, Małgorzata Salamonowicz-Bodzioch, Aleksandra Królak, Krzysztof Kałwak, Joanna Owoc-Lempach, Jerzy Kowalczyk, Joanna Zawitkowska, Tomasz Szczepański, Ninela Irga-Jaworska, Elżbieta Adamkiewicz-Drożyńska et al.
Cancers 2024, 16(15), 2640; https://doi.org/10.3390/cancers16152640
Available online: https://www.mdpi.com/2072-6694/16/15/2640

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office